OneSource Specialty Pharma Share Price

Onesource Specialty Pharma Limited was initially incorporated as a Private Limited Company, as Inbiopro Solutions Private Limited' dated June 12, 2007, with the Registrar of Companies, Karnataka at Bangalore. The name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company converted into a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021 and subsequently, it changed to Onesource Specialty Pharma Limited' on February 13, 2024. In FY 2024-25, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively. Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/- each have been allotted and issued. At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated R&D houses, spread across the globe. The Company became the first and only CDMO with the launch of semaglutide first in India and then Canada across the multiple customer brands in 2026.